Bristol-Myers and Incyte to launch Phase 3 studies of drug combination
Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »
Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »
Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »
Alkermes PLC has launched a Phase 3 study for its product ALKS 8700 – a novel, oral monomethyl fumarate drug in development that will be used for patients with relapsing forms of multiple sclerosis. Read More »
Alkermes PLC will present data for the two-month dosing option of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia at the 16th International Congress on Schizophrenia Research in San Diego Friday through Monday. Read More »
Incyte Corp. will conduct a multi-year research project in conjunction with the Abramson Cancer Center at the University of Pennsylvania aimed at advancing the understanding of cancer biology. Read More »
The European Commission has granted Eli Lilly & Co. marketing rights for Olumiant, a drug used to treat patients suffering with severe rheumatoid arthritis. Read More »
Incyte Corp. and Merus N.V. have a new partnership to study and develop a platform around bispecific antibodies using Merus’ proprietary Biclonics technology platform. Read More »
The agreements allow AstraZeneca to focus on its main therapy areas. Read More »
The research support and collaboration is focused on developing therapies for specific blood cancers. Read More »
Licensing agreement gives Grünenthal GmbH exclusive rights in Europe and Latin America. Read More »
Incyte Corp. announced that approximately 20 abstracts associated with its clinical developments will be presented at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) meetings in 2016. Read More »
AstraZeneca completed the acquisition of Takeda's core respiratory business recently. Read More »
Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »
Selumetinib is being evaluated for treatment of stage III or IV differentiated thyroid cancer. Read More »
Incyte will also obtain the license for Inclusig in Europe and 22 other countries. Read More »
AstraZeneca sells global rights outside of the U.S. to China Medical System Holdings Ltd. Read More »
AstraZeneca announced the positive decision for CAZ AVI by CHMP. Read More »
Zurampic has been approved by the FDA for treatment of hyperuricemia associated with gout. Read More »
AstraZeneca and its R&D arm, MedImmune, announced its integrated genomics initiative this week. Read More »
AstraZeneca and its R&D arm, MedImmune, to present abstracts, oral presentations and lectures in New Orleans. Read More »